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Abstract
Background: A reduced exercise capacity is associated with increased morbidity and mortality in patients with
advanced non-small cell lung cancer (NSCLC). Therapeutic exercise can be beneficial and neuromuscular electrical
stimulation (NMES) of the quadriceps muscles may represent a practical approach. The primary aim of this study
was to determine the acceptability of NMES of the quadriceps to patients with NSCLC used alongside palliative
chemotherapy. Secondary aims explored aspects of safety and efficacy of NMES in this setting.
Methods: Patients with advanced NSCLC due to receive first-line palliative chemotherapy were randomized to usual
care with or without NMES. They were asked to undertake 30 minute sessions of NMES, ideally daily, but as a
minimum, three times weekly. For NMES to be considered acceptable, it was predetermined that ≥80% of patients
should achieve this minimum level of adherence. Qualitative interviews were held with a subset of patients to explore
factors influencing adherence. Safety was assessed according to the Common Terminology Criteria for Adverse
Events. Quadriceps muscle strength, thigh lean mass, and physical activity level were assessed at baseline and after
three cycles of chemotherapy.
Results: 49 patients (28 male, median (IQR) age 69 (64−75) years) participated. Of 30 randomized to NMES, 18
were eligible for the primary endpoint, of whom 9 (50% [90% CI, 29 to 71]) met the minimum level of adherence.
Adherence was enhanced by incorporating sessions into a daily routine and hindered by undesirable effects of
chemotherapy. There were no serious adverse events related to NMES, nor significant differences in quadriceps
muscle strength, thigh lean mass or physical activity level between groups.
Conclusions: NMES is not acceptable in this setting, nor was there a suggestion of benefit. The need remains to
explore NMES in patients with cancer in other settings.
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Introduction
In patients with advanced non-small cell lung cancer
(NSCLC), a reduced exercise capacity is associated with
increased morbidity and mortality [1,2]. Causative factors
include the cancer, via the cachexia syndrome [3,4], and
cancer treatments, with patients receiving palliative
chemotherapy experiencing an overall deterioration in muscle
PLOS ONE | www.plosone.org 1 December 2013 | Volume 8 | Issue 12 | e86059
strength, lean body mass and physical activity level [5,6]. In
part, these effects arise from chemotherapy-related fatigue
contributing towards a negative cycle of reduced physical
activity and muscle deconditioning [7].
Therapeutic exercise may help mitigate these effects [1,8]
and exercise programmes with aerobic and/or resistance
training have been explored in patients with advanced NSCLC
[9-11]. However, limitations include relatively low rates of
uptake and adherence, and inconsistent benefit, which may be
limited to select well motivated patients [9,11].
Neuromuscular electrical stimulation (NMES) of the lower
limb muscles is a form of exercise undertaken whilst seated,
which requires less motivation and change in lifestyle than
traditional exercise. It could provide a pragmatic alternative,
particularly for those patients experiencing exercise-limiting
symptoms, e.g. breathlessness. Further, patients with
advanced cancer have expressed a general preference for
NMES over traditional forms of exercise [12]. Although NMES
offers no aerobic training, improvements in quadriceps strength
and exercise capacity have been achieved in patients with
advanced disease [13,14]. A pilot study undertaken by our
group in patients with advanced NSCLC who had completed
chemotherapy, suggested NMES warranted further study [15].
However, given the deleterious effects of palliative
chemotherapy, we considered it appropriate to formally explore
the acceptability of NMES in this setting before attempting a
large confirmatory study. Thus, in conjunction with the UK
National Cancer Research Institute Palliative Care Clinical
Studies Group we developed a phase II trial with the primary
aim to determine if NMES is an acceptable exercise
intervention for patients with NSCLC receiving first-line
palliative chemotherapy. Secondary aims were to examine
aspects of safety and efficacy of NMES.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Participants
Eligible patients were identified from thoracic oncology clinics
at a large teaching hospital (Nottingham University Hospitals
NHS Trust) and a smaller neighbouring hospital (Sherwood
Forest Hospitals NHS Foundation Trust) between September
2010 - May 2012 and September 2011 – May 2012
respectively (Figure 1; study flowchart). Inclusion criteria were:
adults with advanced (stage IV) NSCLC confirmed by histology
or cytology, an Eastern Cooperative Oncology Group (ECOG)
performance status of 0–2, and scheduled to receive first-line
palliative chemotherapy. Exclusion criteria were spinal cord
compression, epilepsy or cardiac pacemaker. Participants gave
written informed consent and the study was approved by
Nottingham 1 Research Ethics Committee (ref. 09/H0403/24)
and registered with Current Controlled Trials (ISRCTN
42944026).
Procedures
Patients were randomized by the Wales Cancer Trials Unit
using permuted blocks 1:1 into NMES or control (no NMES)
groups. In September 2011, because of slower than anticipated
recruitment, this ratio was amended to 2:1 in favour of NMES,
along with the opening of a second recruiting site. Stratification
factors were age (≤/>65), gender and concurrent use of long-
term oral corticosteroids. Assessments took place before
chemotherapy commenced and repeated during the third week
of the third cycle of chemotherapy (i.e. after 9 weeks).
Assessments were carried out at the hospital except for
physical activity level, which was assessed under free-living
conditions over the week prior to the hospital visit. Outcome
assessors were not blinded to the patient group allocation.
Neuromuscular electrical stimulation
Delivered by a MicroStim Exercise Stimulator MS2v2
(Odstock Medical Ltd, Wiltshire, UK) with two 7cm round
PALS® Platinum self-adhesive electrodes (Axelgaard
Manufacturing Co Ltd, Denmark) placed on the anterior thigh
over the quadriceps. Stimulation parameters were chosen to
minimise fatigue and skin irritation whilst producing meaningful
muscle contraction: (i) symmetrical biphasic squared pulses at
50Hz frequency, (ii) 350 microsecond pulse width, (iii) duty
cycle increasing on a weekly basis from 11% to 18% to 25%
and remaining constant thereafter [16]. The amplitude (device
output 0–120mA, tested across 1000Ω) was initially set to elicit
a visible and comfortable muscle contraction and patients were
encouraged to increase the amplitude as tolerated. The
research team supervised the first training session, offered
written instruction and made contact weekly by telephone to
provide feedback and adjust stimulation parameters. Patients
were instructed to undertake bilateral thigh stimulation for 30
minutes, ideally daily, but as a minimum three times a week.
This began one week after commencement of chemotherapy
and continued for 8 or 11 weeks, dependent on patients
receiving 3 or 4 cycles of chemotherapy respectively.
Assessments
Acceptability.  Assessed by patients' adherence to the
recommended programme of NMES through self-report daily
diaries over the initial 8 week period. At the end of the NMES
intervention, a subset of patients was invited to complete semi-
structured interviews to explore factors influencing adherence
using inductive thematic analysis [17].
Quadriceps muscle strength.  Assessed using a Manual
Muscle Tester dynamometer (Lafayette Instruments, USA)
mounted on a custom-built rig. Patients were seated with hips
and knees at 90° and the dynamometer placed just above the
ankle of the dominant leg. Patients pushed as hard as possible
against the dynamometer for three seconds, whilst the
assessor prevented any movement to ensure an isometric
contraction. Following a familiarisation test, patients undertook
three attempts with standardised verbal encouragement and
the peak force (kilograms, kg) maintained for over half a
second was recorded.
Body composition.  thigh and whole body lean tissue mass
were determined using dual-energy X-ray absorptiometry
NMES in NSCLC during Chemotherapy
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(LUNAR Prodigy Advanced, GE Lunar, Madison, USA) with
enCORE software (Version 13.6) using standard imaging and
positioning protocols [18].
Physical activity level.  Mean daily step count and time
spent in an upright posture, i.e. standing or walking, were
measured over six days using an ActivPAL™ accelerometer
Figure 1.  Study flow diagram.  
doi: 10.1371/journal.pone.0086059.g001
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(PAL technologies Ltd, Glasgow, UK). This is worn on the mid-
thigh continuously except for when showering or bathing. It is
accurate over a wide range of walking speeds and daily activity
and not falsely triggered by travel in a motor vehicle [19-21].
Nutritional intake.  Mean daily protein (g/d) and energy
(kcal/d) intake were calculated using NetWISP (V3.0, Tinuviel
Software, UK) based on a prospective 3-day diary which
included one weekend and two week days.
Fatigue.  Assessed using the Multidimensional Fatigue
Inventory (MFI-20), a 20-item scale with five domains (general,
physical and mental fatigue, reduced activity, and reduced
motivation) [22,23]. A change in subscale score of 3−4 is
considered clinically important [24].
Quality of life.  Assessed using the multidimensional
European Organisation for the Research and Treatment of
Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-
C30) and the lung cancer module (LC-13) [25,26]. A change in
subscale score of ≥10 is considered clinically important [27].
Safety relating to NMES.  Assessments were reported in
real time according to the Common Terminology Criteria for
Adverse Events (version 4.0) of the National Cancer Institute
[28].
Response to chemotherapy.  Evaluated by Response
Evaluation Criteria in Solid Tumors (RECIST) guidelines
version 1.1 [29].
Statistical analysis
The primary endpoint for acceptability was the proportion of
patients in the NMES group reaching the predetermined
minimum level of adherence to the recommended programme,
i.e. three times every week over an 8 week period. Following
advice from the National Cancer Research Institute Palliative
Care Clinical Studies Group, we determined a priori that ≥80%
of patients should adhere to this minimum level in order to
warrant a phase III study in this setting and if ≤50% adhered,
this would give grounds to reject further study. Using a
Fleming's single-stage method (p1=0.5; p2=0.8; α=0·05; 90%
power), we needed to recruit 20 patients in the NMES group
and if ≥15 out of 20 patients adhere, this would warrant further
investigation [30]. Participants discontinuing the intervention or
withdrawing from the study because of a NMES-related
undesirable effect were considered in the analysis but
classified as non-adherent. Continuous data were expressed
as median and inter-quartile range [IQR]. Patient
characteristics were compared between control and NMES
groups using the Wilcoxon rank sum test or exact Pearson chi-
square test. Categorical data were expressed as proportions.
Changes in secondary outcomes were compared between
groups by mean differences with 95% confidence intervals in
an exploratory per protocol analysis. All calculations were
performed using Stata version 11. P values <0.05 were
regarded as statistically significant.
Results
Participants
Of 85 eligible patients approached, 49 were recruited. Fifteen
(50%) of 30 patients randomised to the NMES group and 13
(68%) of 19 patients in the control group completed three
cycles of chemotherapy (Figure 1). Assessments were
completed in full except for body composition, missing in eight
patients due to inability to obtain a scan before chemotherapy
started (n=5) or because of patient choice (n=3); a self-report
diary was not returned in one patient who deteriorated and
died. Participants (28 male) had a median (IQR) age of 69
(64−75) years, body mass index of 25.3 (21.5−28.1) kg/m2 and
percentage weight loss from a pre-illness stable baseline of 1
(0−1) %. Twenty four (49%) met criteria for cancer cachexia
based on one or more of: low appendicular skeletal muscle
index (n=17); >5% weight loss (n=13), or body mass index
<20kg/m2 (n=4)31. Chemotherapy regimens were platinum-
based (carboplatin or cisplatin) generally combined with either
vinorelbine or pemetrexed. As of 1st October 2012, 33 patients
have died with a median [IQR] survival of 23 [19−31] weeks.
There were no significant baseline differences between NMES
and control groups, except that a higher proportion of patients
in the control group met the criteria for cachexia (63% vs. 40%,
p=0.01) (Table 1).
Two of the 30 patients randomised to NMES rapidly
deteriorated and died before receiving chemotherapy or the
intervention. Of the remaining 28 patients, 10 did not complete
three cycles of chemotherapy due to either clinical deterioration
alone (n=2) or clinical deterioration and chemotherapy toxicities
(n=8) which resulted in three further deaths. Three further
patients withdrew due to NMES-related muscle discomfort
(Figure 1). In comparison, of the 19 patients randomised to the
control group, 6 did not complete three cycles of chemotherapy
due to clinical deterioration which resulted in death (n=2) or
early cessation of chemotherapy (n=4).
Acceptability
Of the 28 patients who began NMES, seven reported initial
muscle discomfort (CTC grade I) with three patients
withdrawing from the study; the remaining four continued with
NMES and the discomfort eased within a week.
Eighteen patients were eligible for the primary endpoint, i.e.
15 completing three cycles of chemotherapy together with the
three who withdrew secondary to NMES-related muscle
discomfort. Overall, nine (50% [90% CI, 29 to 71]) met the
minimum adherence criterion of undertaking NMES three times
weekly. Although two patients short from the required 20
patients in the original power calculation, for NMES to warrant
further study would require ≥13 out of 18 to adhere (85%
power).
The qualitative interviews revealed that adherence was
enhanced by patients incorporating NMES sessions into a daily
routine. Conversely, adherence was hindered by undesirable
effects of chemotherapy, including hospitalisation, or when
NMES sessions were perceived as not part of ‘normal’ life or
interfered with social activity.
Safety
There were no serious adverse events related to NMES. Six
patients (21%) randomized to NMES were admitted to hospital
during the study period. Precipitating factors were disease
progression (n=2), infection, seizure (presenting feature of
NMES in NSCLC during Chemotherapy
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previously unknown brain metastases) and chemotherapy-
related toxicity (one each of neutropenic sepsis, anaemia). In
comparison, three patients (18%) in the control group were
Table 1. Patient characteristics.
 NMES (n=30) Control (n=19)
Sex (m / f) 16 / 14 12 / 7
Age (years) 70 (64−74) 68 (63−73)
ECOG performance status (0 / 1 / 2) 4 / 19 / 7 4 / 12 / 3
Diagnosis   
adenocarcinoma 15 9
squamous cell 11 8
large cell 0 1
undifferentiated 4 1
Chemotherapy   
carboplatin + vinorelbine 16 9
carboplatin + pemetrexed 12 8
Cisplatin 2 1
cisplatin + pemetrexed 0 1
Medication   
antihypertensive   





low molecular weight heparin 3 0
Statin 11 4
inhaled bronchodilator / corticosteroid 19 11
analgesic   
non-opioid 13 6
weak opioid 13 5
strong opioid 7 5
antidepressant (neuropathic pain) 1 1
anti-epileptic (neuropathic pain) 2 1
antidepressant 2 3
anxiolytic sedative 4 2
long-term oral corticosteroid 5 2
Weight (kg) 66.9 (59.9−76.0) 69.8 (61.1−80.1)
Body mass index (kg/m2) 27.0 (21.4−28.8) 25.1 (22.8−27.2)
% weight loss 0 (0−5.7) 0 (0−4.4)
Nutritional intake   
daily protein (g/day) 73 (64−88) 80 (65−100)
daily caloric intake (kcal/day) 1796 (1536−2179) 2077 (1708−2509)
Body composition   
whole body lean mass (kg) 47.5 (35.6−52.1)a 49.6 (36.2−53.1)b
Met criteria for cachexia (n, %) (12, 40) (12, 63)
low appendicular skeletal muscle indexc 8 9
5% weight loss 8 5
body mass index <20kg/m2 3 1
Quadriceps muscle strength (kg) 16.4 (11.7−20.9) 20.5 (16.5−23.1)
Mean daily physical activity level   
step count 3146 (2040−3831) 3193 (1740−4644)
upright time (min) 232 (159−308) 194 (165−264)
up/down transitions 47 (35−60) 43 (33−58)
Survival (weeks) 27 [19-35] 23 [5-41]  
admitted to hospital because of cancer-related disseminated
intravascular coagulation, infection or neutropenic sepsis.
Physical performance
Fifteen patients in the NMES group and 13 patients in the
control group completing three cycles of chemotherapy were
available for analysis of the secondary outcome measures
(Table 2). The proportion of patients in either group with stable
disease (47% vs. 54%) or a partial response (33% vs. 38%)
following chemotherapy were similar. A higher proportion of
patients in the NMES group had progressive disease (20% vs.
8%) but this difference was not significant (p=0.76).
Compared to baseline, after three cycles of chemotherapy,
there were no significant differences between the NMES and
control groups in changes in quadriceps muscle peak strength,
thigh lean mass or aspects of physical activity (Table 2).
Although fatigue generally increased in both groups, there was
a significant difference in the mental fatigue subscale (median
change 0 vs. 3; p=0.03) favouring the NMES group, which
would be considered clinically important (Table 2) [24].
Generally, quality of life deteriorated in the control group and
remained unchanged in the NMES group. However, none of
the changes were statistically significant between groups
(Table 2).
Discussion
The main finding of this phase II randomized controlled study
is that NMES, based on our criteria, is not sufficiently
acceptable alongside first-line palliative chemotherapy in
patients with NSCLC to justify a phase III study in this setting.
In addition, an exploratory per protocol analysis found no
significant differences between the NMES and control groups
with regard to quadriceps muscle strength, thigh lean mass or
physical activity level. In the absence of the above, it is unlikely
that the statistically significant difference found in the
exploratory analysis of fatigue represents a specific effect of
NMES.
Strengths of the study include an adequate sample size to
explore the primary aim with sufficient power, the use of a
programme of NMES shown to be effective in other settings
[13], and a definition of adherence agreed a priori. A high
uptake to the study by those approached (58%) increases the
generalizability of the findings to this patient population. Our
experience provides useful data with regards to recruitment
and attrition rates for those planning similar supportive care
studies alongside palliative chemotherapy. The secondary
Table 1 (continued).
Data are median (IQR) or n,%.
a based on 22 patients
b based on 15 patients
c males <7.26 kg/m2; females <5.45 kg/m2
doi: 10.1371/journal.pone.0086059.t001
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outcome assessment data and the embedded qualitative work
can also be used to inform future trials.
The main weakness of the study is the reliance on patient
reports of frequency and duration of use of NMES. Generally,
patient reports of exercise undertaken tend to overestimate that
actually done [32]. Thus, it could be that even those adhering
to the programme overestimated their use of NMES and is one
possible explanation why we found no overall benefit unlike
others using a similar programme [13].
It could be argued that our adherence criteria were too rigid,
e.g. a minimum of three NMES sessions per week, every week,
and that our cut off to warrant further study was set too high,
i.e. ≥80% of patients adhering. Certainly, three patients who
failed to meet the minimum adherence criterion did so by
missing only one session of NMES on one week. A more
flexible overall minimum ‘dose’ criterion may be more
appropriate for future studies. The high cut off reflects the level
of adherence seen in our pilot study where daily use was
recommended [15], and ensured that NMES would be
performing similar or better in this regard compared to
traditional exercise programmes [33].
Other potential limitations include the methods used to
assess quadriceps muscle strength and bulk, i.e. hand-held
dynamometry and DEXA scan [13]. Although more accurate
assessments are available, e.g. fixed dynamometry [34] and
magnetic resonance imaging [35], our selection was based on
pragmatism, with a future multicenter study in mind. A lack of
patient and assessor blinding could have introduced bias,
although possible evidence for this is limited to non-significant
differences in quality of life domains in the NMES group.
To our knowledge, this is the first study to examine the use
of NMES alongside palliative chemotherapy and there are no
directly comparable studies. In our randomized pilot study
(n=16), when patients with advanced NSCLC who had
completed chemotherapy were asked to use NMES 30 minutes
daily for one month, median (range) reported adherence was
higher at 80% (69–100). There was also more of a suggestion
of global benefit from NMES with favourable changes in
quadriceps strength, exercise endurance and physical activity,
albeit statistically non-significant [15]. Possible explanations for
the difference in findings include the populations studied and
the treatment ‘dose’ of NMES. Although in the current study we
explored the use of NMES earlier in the patients’ journey,
paradoxically, this group had a poorer prognosis than those in
the pilot study (i.e. median survival of 23 vs. 40 weeks) and
thus, potentially less scope for benefit from NMES [15].
Patients received a lower ‘dose’ of NMES than in the pilot
study. Although advised to use NMES ideally daily, in an
attempt to ensure reasonable adherence over a longer period,
we specified the minimum schedule associated with benefit, i.e.
three treatments per week [13]. Our data suggest that
unintentionally, many patients saw this as the target to aspire
to and that the additional symptom and schedule burden of
chemotherapy, along with periods of hospitalisation,
contributed to a lower level of use.
Although a higher treatment ‘dose’ of NMES should
theoretically be more beneficial, this is likely to be impractical
Table 2. Secondary outcomes expressed as median (IQR) (exploratory per-protocol analysis).
 NMES (n=13)
a Control (n=12)a p
 Baseline Post-chemo Change Baseline Post-chemo Change  
Quadriceps muscle strength (kg) 16.4 (11.7−20.9) 17 (13.1−19.3) -0.1 (-1.9−2.7) 22 (18.4−23.1) 22 (19.2−25.4) -2.1 (-3.4−2.7) 0.29
Body composition        
Thigh lean mass (kg) 6.1 (4.7−6.5) 6 (3.9−6.9) 0 (-0.4−0.6) 6.3 (4.2−6.4) 6.3 (4−6.6) -0.2 (-0.3−0.2) 0.44
Whole body lean mass (kg) 48.9 (34.6,50.9) 45.4 (35.7,48.3) -0.4 (-2.6−0.8) 49 (36.2−53.1) 51.2 (34−62.2) -0.3 (-1.5−3.5) 0.31
Mean daily physical activity level        
Step count 3163 (2267−3855) 2766 (2053−4482) -246 (-431−503) 3362 (2818−4644) 3332 (2636−4429) 51 (-1736−238) 1.00
Time upright (min) 268 (184−331) 208 (124−297) -42 (-68−17) 190 (165−228) 160 (142−262) -7 (-48−26) 0.38
Up/down transition 56 (45−73) 54 (42−65) -5 (-13−5) 41 (33−61) 43 (37−59) 1 (-17−8) 0.66
Fatigue (lower better)        
General 13 (12−15) 13 (13−14) -1 (-2−2) 11 (8−12) 13 (9−15) 1 (0−2) 0.14
Physical 13 (10−15) 13 (12−15) 0 (-1−2) 9 (5−14) 13 (11−15) 2 (0−7) 0.16
Reduced activity 16 (9−17) 12 (9−15) 0 (-1−1) 10 (5−16) 13 (10−14) 2 (-3−6) 0.26
Reduced motivation 10 (8−12) 8 (6−10) -1 (-2−1) 10 (5−12) 10 (8−14) 2 (1−2) 0.08
Mental fatigue 9 (6−11) 8 (5−11) 0 (-4−2) 4 (4−7) 9 (5−12) 3 (0−6) 0.03
Quality of life (higher better)        
General health score 58 (42−67) 50 (50−67) 8 (-8−17) 67 (67−92) 67 (58−75) -8 (-33−8) 0.22
Physical 73 (40−87) 67 (67−80) 0 (-7−13) 87 (73−93) 80 (60−87) 0 (-13−13) 0.47
Role 67 (50−83) 83 (66−100) 17 (0−17) 83 (67−100) 66 (66−83) 0 (-33−0) 0.06
Emotional 83 (75−92) 92 (67−100) 0 (0−8) 92 (92−100) 100 (75−100) 0 (-8−8) 0.71
Cognitive 83 (67−100) 83 (83−100) 0 (0−0) 100 (83−100) 83 (67−100) 0 (-17−0) 0.18
Social 83 (50−100) 100 (50−100) 0 (0−17) 100 (83−100) 100 (50−100) 0 (-33−0) 0.21
a Only patients with both baseline and post-chemotherapy data included.
doi: 10.1371/journal.pone.0086059.t002
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given the challenges this group face with regard to morbidity
related to their disease and chemotherapy. In this regard,
NMES is unlikely to offer any distinct advantage over other
traditional forms of exercise. Further, given we found little
decline in our secondary outcome measures in those patients
completing three cycles of treatment, the rationale for the use
of NMES alongside chemotherapy, at least for this patient
group receiving these treatment regimens, could be
questioned.
Nonetheless, the need remains for adequately powered
studies to examine if NMES can provide meaningful benefit to
patients with NSCLC in other settings, either given alone, or as
part of a combined approach, e.g. with nutritional support, anti-
inflammatory drug or more specific anti-cachexia treatment
[36]. Based on our findings, we would suggest patients are
recruited after completing chemotherapy and that daily
treatment is advised, rather than a minimum.
In conclusion, based on our criteria, NMES is not an
acceptable exercise intervention alongside first-line palliative
chemotherapy in patients with NSCLC. Poor adherence and
high rates of attrition contribute towards a lack of overall benefit
in this setting. The need remains to identify if NMES is of
benefit in patients with cancer in other settings.
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